Outcome measures
cataract, ocular adverse, CMT
CATARACT, PROLIFERATIVE DIABETIC RETINOPATHY (PDR), ADVERSE EVENTS, LOSS OF VISION
The primary outcome measure was the number of intravitreal aflibercept injections in each of the two treatment arms at 24 months. Secondary outcome measures at 24 months compared with baseline included: the proportion of eyes that have central macular thickness (CMT) < 300 µm, mean change in CMT, mean change in best corrected visual acuity (BCVA) and mean treatment interval.Safety outcomes measures included: the incidence of rescue macular laser, the incidence of ocular adverse events including severe (>15 letter) loss of vision, new proliferative diabetic retinopathy (PDR), cataract progression and the incidence of non-ocular adverse events.